Pancreatic Cancer Therapeutics Market to reach USD 3.47 billion by 2023

Recent Developments:

Eli Lilly and Company is a large global pharmaceutical company, Lilly is currently the largest manufacturer of psychiatric medications and generates Prozac (fluoxetine), Dolophine Cymbalta (duloxetine), (methadone), and Zyprexa (olanzapine). In 2017 Lilly continued for the advance promising new treatments in multiple therapeutic areas, including diabetes, oncology, immunology, pancreatic cancer, Alzheimer’s disease and pain.

In March 2017, the company get CoLucid Pharmaceuticals for $960 million, specifically gaining the late clinical-stage migraine therapy candidate, lasmiditan.

In May 2018, the company get Armo Biosciences for $1.6 billion, later the company announced it would acquire Aurora kinase A inhibitor developer - AurKa Pharma- and manage over the lead compound, AK-01, for up to $575 million.

To know more read: https://www.marketdataforecast.com/market-reports/global-pancreatic-cancer-market-1277/

Market Segmentations:

Global Pancreatic Cancer Therapeutics Market worth was USD 2.41 billion in 2018 and estimated to be growing at a CAGR of 7.54%, to reach USD 3.47 billion by 2023

Report is segmented by
Disease
• exocrine pancreas cancer
• endocrine pancreas cancer
End users
• hospitals
• clinics
• research institutes

Based on disease, pancreatic cancer occurs when there is an uncontrollable development of cells in the pancreas, pancreatic cancer is the 12th-most common cancer in the world. The approximated five-year prevalence of people living with pancreatic cancer is 4.1 per 100,000, globally. This leads to growth of drugs and diagnostic technology, and emphasis on early diagnosis, which are driving the growth of the current market.

Geographical Segmentation:

Based on geography, the market is analyzed under many countries namely, North America, Europe, Asia-Pacific, Latin America and Middle-East & Africa. Globally North America is the large market for pancreatic cancer.

Key market players in the market are:

Some of the major key players dominating the market are Eli Lilly, Amgen Inc, Celgene Corp, F. Hoffmann-La Roche, Clovis Oncology Inc, Pfizer, Novartis AG, Threshold Pharmaceuticals Inc, Aduro BioTech Inc, Infinity Pharmaceuticals Inc, NewLink Genetics Corp

View sample and decide: https://www.marketdataforecast.com/market-reports/global-pancreatic-cancer-market-1277/request-sample

Scope of the report:

The report gives a comprehensive analysis of the industry by providing the estimations of market potential and forecasts with utmost granularity. Along this, the factors influential in effecting the current market dynamics and trends are discussed in detail at the product level. Further, the performance of the current market at the regional and country-level is measured and the prospects with high growth potential are identified and debated.
The key players in the industry are profiled providing insights on their financial performance, market position and the growth strategies.

Comparative analysis on key strategically activities of the market players delineating the key developments like mergers and acquisitions, collaborations and an evaluation of the competitive environment within the industry are provided. The report also gives a broad outlook of the market along with recommendations from industry experts on the opportunities for investment activity.

What else? Apart from the syndicated report, our in-house team has an expertise and experience in designing custom reports to meet your specific research needs and assist you in making well-informed decisions.

About Us:

Market Data Forecast is dedicate working in the areas of market research, business intelligence and consulting. We have a great experience in research and consulting for different business domains to cater the needs of both individual and corporate clients.

For more information:

Abhishek Shukla
Sales Manager at Market Data Forecast
Email: abhishek@marketdataforecast.com
Tel: +1-888-702-9626
Website: www.marketdataforecast.com

This release was published on openPR.